Company profile
Femasys Inc.
NASDAQ: FEMY · Healthcare · Medical - Instruments & Supplies
#784 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
41DFH 28DQ 44GM 72SS 39
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), 3-yr revenue growth · ↓ return on equity, listing tenure
Methodology →Revenue TTM
$2.4M
Rev growth YoY (TTM)
+39.9%
Net income (FY)
-$18.6M
Employees
53
as of 2026-08-22
Market cap
$8.9M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.3M$2.3M2025
Net income-$18.6M-$18.6M2025
Operating income-$17.6M-$17.6M2025
Total assets$20.7M$20.7M2025
Liabilities$14.9M$14.9M2025
Equity$5.9M$5.9M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Femasys Inc.’s revenue?
Femasys Inc. booked $2.3M in FY2025 revenue, growing 41% year over year — faster than most Healthcare companies we track, at a -812.3% net margin.
Peers · Healthcare
Panacea Life Sciences Holdings, Inc.——Perimeter Medical Imaging AI, Inc.39DElicio Therapeutics, Inc.24DAdynxx, Inc.——Horizon Space Acquisition II Corp.——Aligos Therapeutics, Inc.47DNeighbors
Gwinnett →Key facts
CEOKathy Lee-Sepsick
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersSuwanee, GA
ExchangeNASDAQ: FEMY
Employees53
IPO date2021-06-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.